Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
180 hedge funds and large institutions have $756M invested in Eagle Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 55 reducing their positions, and 18 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 55
11% more capital invested
Capital invested by funds: $679M → $756M (+$76.4M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 182 → 180 (-2)
25% less call options, than puts
Call options by funds: $7.99M | Put options by funds: $10.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$13.3M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$8.05M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$7.04M |
| 4 |
Man Group
London,
United Kingdom
|
+$6.3M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$21.5M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$14.7M |
| 3 |
Millennium Management
New York
|
-$9.49M |
| 4 |
HEC
Hudson Executive Capital
New York
|
-$8.3M |
| 5 |
Two Sigma Investments
New York
|
-$4.9M |
EGRX Hedge Fund Activity: Q2 2019 in Review
180 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2019, worth a combined $756M — up 11% from $679M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EGRX positions and 18 closed out — a net gain of 1 holder — while 67 added to existing stakes and 55 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $13.3M. The largest seller was JW Asset Management, exiting entirely with an estimated $21.5M sold.
- 180 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2019, down from 182 in Q1 2019.
- Funds reported $756M of Eagle Pharmaceuticals, Inc. stock for Q2 2019, up 11% quarter-over-quarter.
- 19 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2019 and 18 closed out, a net change of +1 holder.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2019 was Park West Asset Management, an estimated $13.3M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2019 was JW Asset Management, an estimated $21.5M sold.
Based on aggregated 13F filings for Q2 2019.